These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 19660031)

  • 1. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
    Tietze LF; Krewer B
    Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric synthesis and biological evaluation of glycosidic prodrugs for a selective cancer therapy.
    Tietze LF; von Hof JM; Krewer B; Müller M; Major F; Schuster HJ; Schuberth I; Alves F
    ChemMedChem; 2008 Dec; 3(12):1946-55. PubMed ID: 19021160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological studies of different duocarmycin based glycosidic prodrugs for their use in the antibody-directed enzyme prodrug therapy.
    Tietze LF; Schuster HJ; Krewer B; Schuberth I
    J Med Chem; 2009 Jan; 52(2):537-43. PubMed ID: 19143570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins.
    Tietze LF; Major F; Schuberth I; Spiegl DA; Krewer B; Maksimenka K; Bringmann G; Magull J
    Chemistry; 2007; 13(16):4396-409. PubMed ID: 17455190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate.
    Torgov MY; Alley SC; Cerveny CG; Farquhar D; Senter PD
    Bioconjug Chem; 2005; 16(3):717-21. PubMed ID: 15898742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
    Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
    Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study on glycosylated prodrugs of toxoflavins for antibody-directed enzyme tumor therapy.
    Wang S; Liu D; Zhang X; Li S; Sun Y; Li J; Zhou Y; Zhang L
    Carbohydr Res; 2007 Jul; 342(9):1254-60. PubMed ID: 17412311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT.
    Tietze LF; Schmuck K; Schuster HJ; Müller M; Schuberth I
    Chemistry; 2011 Feb; 17(6):1922-9. PubMed ID: 21274943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
    Tietze LF; Krewer B
    Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
    Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
    Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enantio- and diastereoselective synthesis of duocarmycine-based prodrugs for a selective treatment of cancer by epoxide opening.
    Tietze LF; Schuster HJ; Hampel SM; Rühl S; Pfoh R
    Chemistry; 2008; 14(3):895-901. PubMed ID: 18033701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
    Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
    Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.
    Zhao RY; Erickson HK; Leece BA; Reid EE; Goldmacher VS; Lambert JM; Chari RV
    J Med Chem; 2012 Jan; 55(2):766-82. PubMed ID: 22148292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
    Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog.
    Wang Y; Jiang J; Jiang X; Cai S; Han H; Li L; Tian Z; Jiang W; Zhang Z; Xiao Y; Wright SC; Larrick JW
    Bioorg Med Chem; 2008 Jul; 16(13):6552-9. PubMed ID: 18508273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosidic prodrugs of highly potent bifunctional duocarmycin derivatives for selective treatment of cancer.
    Tietze LF; von Hof JM; Müller M; Krewer B; Schuberth I
    Angew Chem Int Ed Engl; 2010 Sep; 49(40):7336-9. PubMed ID: 20799305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.